Analyst picks & changes

Analyst picks & changes

Analyst picks & changes
CompanyBankAnalystCoverageOpinionWk chg1/2 cls
Achillion Pharmaceuticals Inc. (NASDAQ:ACHN)BairdBrian SkorneyDowngradeNeutral (from outperform)4%$13.33
Skorney downgraded after data from a Phase I trial to treat HCV showed that ACH-3422 had slower antiviral activity than Sovaldi sofosbuvir from Gilead Sciences Inc.

Read the full 417 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE